All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
On March 30, 2021, the U.S. Food and Drug Administration (FDA) approved an extended indication for CPX-351 (a liposomal formulation of daunorubicin and cytarabine). This means that the label for CPX-351 has been revised to include the treatment of pediatric patients (aged ≥1 year) with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Two studies—AAML1421 and CPX-MA-1201—highlighted the promising safety profile of the regimen in pediatric patients and formed the basis of the extended approval. Data from both studies, alongside those conducted in adult patients, suggest that the safety and toxicity profile of CPX-351 do not differ between age groups.
Jazz Pharmaceuticals plc. Jazz Pharmaceuticals announces FDA approval of additional indication for Vyzeos (daunorubicin and cytarabine) for the treatment of secondary acute myeloid leukemia in pediatric patients. https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-fda-approval-of-additional-indication-for-vyxeos-daunorubicin-and-cytarabine-for-the-treatment-of-secondary-acute-myeloid-leukemia-in-pediatric-patients-301259059.html. Published March 30, 2021. Accessed March 31, 2021.
Outcomes of older patients with secondary AML according to treatment strategy
Lower-intensity strategies such as HMA and LDAC-based regimens are associated with lower early mortality rates and improved OS in comparison to intensive regimen
AAML1421 phase I/II trial of CPX-351 followed by FLAG in children with R/R AML
The treatment and long-term survival of childhood acute myeloid leukemia (AML) is often complicated by the cardiotoxicity of anthracycline use. CPX-351 is a liposomal...
Subscribe to get the best content related to AML delivered to your inbox